Licensing Opportunity – Next-Generation CAR-T for Multiple Myeloma 

This enhanced BCMA-targeting CAR-T technology co-expresses a granzyme B–NOXA fusion protein, overcoming resistance in multiple myeloma by directly neutralizing MCL-1–mediated survival mechanisms.

 Improved tumor killing in vitro & in vivo

 Selective targeting of malignant cells

 Compatible with current CAR-T platforms, including in vivo engineering strategies

 Read the publication in Nature Communications:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089368/

Patent application upon request

We are actively seeking industry partners for licensing and development.

Contact Danielle Counotte to explore this opportunity.